RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Dual LAG-3 and PD-1 inhibition with a fixed-dose combination of relatlimab + nivolumab demonstrated superior PFS compared with nivolumab alone in patients with advanced melanoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 338 KB
Released: June 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Pfizer, Inc.

Related Content

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

On-demand webcast describing how to incorporate new data into current treatment algorithms in melanoma presented by Clinical Care Options (CCO)

Jeffrey S. Weber, MD, PhD
Program Director
Allison Betof Warner, MD, PhD Hussein Tawbi, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 29, 2021 Expired: September 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue